Full Press Release Details
Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., January 6, 2017 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated
to creating small molecule drugs for viral infections and liver diseases, today announced the highlights of its business overview and research and development program update that will be presented at the 35th Annual J.P. Morgan Healthcare Conference on January 11, 2017 at 9:00 a.m. PT. The presentation will provide updates on Enanta s development programs in non-alcoholic steatohepatitis
(NASH)/primary biliary cholangitis (PBC), hepatitis C virus, (HCV), hepatitis B virus (HBV) and respiratory syncytial virus (RSV), as well as an update on the company s HCV assets. In addition, new in vivo data will be presented on
EDP-305, Enanta s lead FXR agonist for NASH and PBC and on EDP-938, Enanta s new non-fusion inhibitor development candidate for RSV.
following are details of Enanta s research and development programs updates and expectations for the coming year.
Research and Development Update:
EDP-305, FXR agonist for NASH:
Respiratory Syncytial Virus (RSV):
Hepatitis B Virus (HBV):
Hepatitis C Virus (HCV):
Enanta s presentation will take place on January 11, 2017 beginning at 9:00 a.m. PT. A live webcast and replay of the presentation, as well as the
question and answer breakout session that follows the presentation will be accessible by visiting the Calendar of Events section on the Investors page of Enanta s website at www.enanta.com. The replay webcasts will be
available following the presentation and will be archived for approximately 60 days.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery
capabilities to create small molecule drugs for viral infections and liver diseases. Enanta s research and development efforts are currently focused on three disease targets: non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis
(PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Enanta has discovered novel protease inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta s collaboration with AbbVie, include paritaprevir, which is contained in AbbVie s
marketed DAA regimens for HCV, and glecaprevir (ABT-493), Enanta s second protease inhibitor product, which AbbVie is developing as part of an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose combination (G/P) with
pibrentasvir (ABT-530), AbbVie s second NS5A inhibitor.
Enanta has discovered EDP-305, an FXR agonist product candidate for NASH and PBC, currently
in Phase 1 clinical development, and has identified a clinical candidate for RSV, EDP-938, now, in preclinical development. Enanta is also developing early lead candidates for HBV. Please visit www.enanta.com for more information on Enanta s
programs and pipeline.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for Enanta s further development of EDP-305,
the prospects for AbbVie s G/P regimen in HCV, and the prospects for further developments in Enanta s RSV and HBV programs. Statements that are not historical facts are based on management s current expectations, estimates, forecasts
and projections about Enanta s business and the industry in which it operates and management s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results
include: the development risks of early stage discovery efforts in new disease areas in Enanta s research and development efforts, such as NASH, PBC, RSV and HBV; the impact of development, regulatory and marketing efforts of others with
respect to competitive treatments for NASH, PBC, RSV, HCV or HBV; regulatory and reimbursement actions affecting any competitive treatment for NASH, PBC, RSV, HCV or HBV; Enanta s limited clinical development experience; Enanta s need to
attract and retain senior management and key scientific personnel; Enanta s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk
factors described or referred to in Risk Factors in Enanta s most recent Form 10-K for the fiscal year ended September 30, 2016 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta
cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except
as may be required by law.
MacDougall Biomedical Communications